Daiichi Sankyo Submits Application for Approval of Levofloxacin Hydrate Injection in Japan

For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, General Manager, Corporate Communications Department Telephone: +81-3-6225-1126 http://www.daiichisankyo.com/ Daiichi Sankyo Submits Application for Approval of Levofloxacin Hydrate Injection in Japan Tokyo, Japan (October 29, 2009) - Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it submitted an application in Japan on October 28 to manufacture and market an injectable preparation of Levofloxacin Hydrate that incorporates the company's new quinolone anti-bacterial agent. Clinical trials have confirmed the injection's excellent clinical efficacy against pneumonia and secondary chronic respiratory infections. Cravit®, an oral Levofloxacin Hydrate agent, already is a widely accepted treatment in formulations of 500mg and 250mg tablets and as a 10% fine granular preparation. The addition of an injectable version in Levofloxacin Hydrate lineup would contribute further to infectious disease treatment. End

The release as fetched from its publisher. daiichisankyo.com ↗